Clinical Trials Browser

Terminated × Interventional × Erlotinib Hydrochloride × Clear all

NCT02991651 2025-05-14

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00448240 2025-03-18

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Phase 2/3 Terminated

6 enrolled 4 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00503971 2025-03-07

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Phase 1/2 Terminated

33 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT01032070 2024-12-12

PETEY

Phase 2 Terminated

25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Phase 2 Terminated

4 enrolled 9 charts

Familial ependymoma, Ependymoma

NCT02495233 2024-11-27

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase 1/2 Terminated

10 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00750698 2023-07-06

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Phase 2 Terminated

8 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00597597 2023-05-17

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Phase 2 Terminated

11 enrolled 12 charts

Breast Neoplasms

NCT01487174 2022-05-13

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT01455389 2022-03-02

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04165031 2021-11-24

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Phase 1/2 Terminated

5 enrolled 9 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT01110876 2021-08-25

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Phase 1/2 Terminated

21 enrolled 8 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT01683422 2021-08-10

Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

Phase NA Terminated

9 enrolled 8 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01244191 2021-04-06

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Phase 3 Terminated

1,048 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT00570258 2021-03-30

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Phase 2 Terminated

27 enrolled 7 charts

Breast Neoplasms

NCT02714530 2021-03-30

ThoRaT

Phase 2 Terminated

Neoplasms

NCT02893332 2021-02-03

Sindas

Phase 3 Terminated

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

NCT00760929 2021-01-05

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Phase 2 Terminated

171 enrolled 17 charts

Non-Squamous Non-Small Cell Lung Cancer

NCT01190241 2020-11-20

TSAP

Phase NA Terminated

Neoplasm Metastasis

NCT02318368 2020-10-22

FOCAL

Phase 2 Terminated

10 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01188707 2020-10-19

A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

Phase 1/2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Phase 2 Terminated

17 enrolled 10 charts

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01038856 2020-08-24

OSI-TAR-766

Phase 2 Terminated

5 enrolled 6 charts

Polycythemia Vera

NCT01857271 2020-07-08

EVENT

Phase 2 Terminated

3 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung

NCT02169284 2020-07-07

Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

Phase 2 Terminated

50 enrolled 27 charts

Urinary Bladder Neoplasms

NCT01192815 2020-05-12

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Phase 2 Terminated

2 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck

NCT00539617 2020-03-23

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

7 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT02926638 2020-03-19

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2/3 Terminated

9 enrolled 5 charts

MET Positive

NCT03460678 2020-03-05

Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

Phase 4 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02468661 2020-02-24

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02117024 2020-02-05

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase 2 Terminated

66 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02770014 2019-11-22

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Phase 2 Terminated

43 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT01182350 2019-09-04

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Phase 2 Terminated

53 enrolled 12 charts

Diffuse Intrinsic Pontine Glioma

NCT01822496 2019-08-05

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2 Terminated

59 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02080078 2019-05-03

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Diarrhea

NCT00503841 2019-04-30

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Phase NA Terminated

44 enrolled 3 charts

Breast Neoplasms

NCT02775006 2019-04-30

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02556593 2019-04-12

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00996502 2019-03-27

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

4 enrolled 2 charts

Prostatic Neoplasms

NCT01518621 2019-03-13

RadEr

Phase 2 Terminated

Neoplasms

NCT00750555 2019-02-26

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Phase 2 Terminated

Head and Neck Neoplasms

NCT01962896 2019-02-26

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Phase 2 Terminated

4 enrolled 6 charts

Neoplasms, Germ Cell and Embryonal

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

NCT01284335 2019-01-10

A Safety Study in Participants With Advanced Solid Tumors

Phase 1 Terminated

234 enrolled 23 charts

Neoplasm Metastasis

NCT00573989 2019-01-03

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Phase 1/2 Terminated

27 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms